biostudies-literatureUnknown9(5)Huang RSP<h4>Introduction</h4>Several studies have shown clinical outcomes data that support the use of <i>CD274 (PD-L1</i>) copy-number (CN) gains and/or losses as a biomarker for immune checkpoint inhibitor (ICPI). Here, we present the landscape of <i>CD274</i> CN changes across a large cohort of solid tumor cases and correlate these with PD-L1 protein expression by immunohistochemistry.<h4>Methods</h4>We analyzed all cases that underwent comprehensive genomic profiling (CGP) testing at Foundation Medicine between August 2014 and June 2020. <i>CD274</i> CN changes were correlated with PD-L1 expression in tumor types where there were Food and Drug Administration approved companion diagnostic (CDx) claims and the CDx assay was used to assess PD-L1 expression.<h4>Results</h4>In all, 244 584 samples Journal for immunotherapy of cancere002680https://www.ebi.ac.uk/biostudies/studies/S-EPMC8112409biostudies-literaturePan-cancer landscape of <i>CD274</i> (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression.PMC8112409Decker BAlbacker LAMurugesan KHiemenz MCHuang RSPMata DAPavlick DCRoss JSMontesion MFrampton GfalsePan-cancer landscape of <i>CD274</i> (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression.<h4>Introduction</h4>Several studies have shown clinical outcomes data that support the use of <i>CD274 (PD-L1</i>) copy-number (CN) gains and/or losses as a biomarker for immune checkpoint inhibitor (ICPI). Here, we present the landscape of <i>CD274</i> CN changes across a large cohort of solid tumor cases and correlate these with PD-L1 protein expression by immunohistochemistry.<h4>Methods</h4>We analyzed all cases that underwent comprehensive genomic profiling (CGP) testing at Foundation Medicine between August 2014 and June 2020. <i>CD274</i> CN changes were correlated with PD-L1 expression in tumor types where there were Food and Drug Administration approved companion diagnostic (CDx) claims and the CDx assay was used to assess PD-L1 expression.<h4>Results</h4>In all, 244 584 samples 2021-01-01T00:00:00Z2021 May2026-07-16T09:57:41.471Z2026-07-09T10:49:40.001ZS-EPMC81124093397239110.1136/jitc-2021-002680